Tejnaksh Healthcare Ltd Upgraded to Sell on Improved Valuation Metrics

Quality Assessment: Weak Fundamentals Persist

Tejnaksh Healthcare continues to exhibit weak long-term fundamental strength, reflected in a negative compound annual growth rate (CAGR) of -14.76% in operating profits over the past five years. This decline underscores persistent operational challenges and an inability to expand core earnings effectively. The company’s average return on equity (ROE) stands at a modest 9.52%, indicating limited profitability generated per unit of shareholders’ funds. The latest reported ROE is even lower at 6.34%, signalling further deterioration in capital efficiency.

These quality metrics remain a concern for investors, as they highlight the company’s struggle to generate sustainable earnings growth and deliver value to shareholders. The flat financial performance reported in Q4 FY25-26 reinforces this narrative, with no meaningful improvement in revenue or profitability trends.

Valuation Upgrade: From Attractive to Very Attractive

The most notable change triggering the upgrade is the valuation grade, which has improved from “attractive” to “very attractive.” Tejnaksh Healthcare’s current price-to-earnings (PE) ratio stands at 25.38, considerably lower than several peers in the healthcare services industry. For comparison, KMC Speciality trades at a PE of 40.13, Suraksha Diagnostics at 45.47, and Gujarat Kidney at a steep 69.71. This valuation discount is further supported by a price-to-book (P/B) value of 1.17, indicating the stock is trading close to its book value and at a discount relative to historical averages and sector benchmarks.

Enterprise value to EBITDA (EV/EBITDA) ratio of 10.86 also positions Tejnaksh Healthcare favourably against peers, many of whom trade at multiples exceeding 14. This valuation repositioning suggests the market is pricing in the company’s challenges but also recognising potential upside if operational performance stabilises or improves.

Financial Trend: Flat Performance Amid Declining Profitability

Despite the improved valuation, Tejnaksh Healthcare’s recent financial trend remains subdued. The company reported flat results in the quarter ending March 2026, with no significant growth in revenue or operating profit. Over the past year, the stock has delivered a negative return of -30.92%, underperforming the Sensex benchmark, which declined by -8.73% over the same period.

More concerning is the sharp decline in profitability, with operating profits falling by approximately -47.9% year-on-year. This contraction in earnings highlights ongoing operational pressures and challenges in cost management or revenue generation. The company’s return on capital employed (ROCE) is 8.28%, which, while positive, remains modest and insufficient to drive strong shareholder returns.

Technicals: Stable Price but Weak Momentum

From a technical perspective, Tejnaksh Healthcare’s share price has been relatively stable in the short term, closing at ₹15.24 on 2 June 2026, unchanged from the previous day. The stock’s 52-week high is ₹23.31, while the low is ₹10.65, indicating a wide trading range and significant volatility over the past year.

Short-term price movements show a mixed picture: a modest 0.79% gain over the past week contrasts with a 4.75% decline over the last month. The stock’s year-to-date return of 1.67% outperforms the Sensex’s -12.85% return, suggesting some resilience despite fundamental weaknesses. However, the longer-term technical trend remains negative, with a three-year return of -54.18% and a five-year return of -50.16%, both substantially lagging the broader market.

Market Capitalisation and Shareholding

Tejnaksh Healthcare is classified as a micro-cap stock, reflecting its relatively small market capitalisation within the healthcare services sector. The majority shareholding is held by promoters, which may provide some stability in ownership but also concentrates control within a limited group.

The micro-cap status often entails higher volatility and risk, which investors should consider alongside the company’s fundamental and valuation profile.

Comparative Industry Positioning

Within the healthcare services sector, Tejnaksh Healthcare’s valuation metrics stand out as particularly attractive relative to peers. While companies such as KMC Speciality and Suraksha Diagnostics trade at significantly higher PE and EV/EBITDA multiples, Tejnaksh’s lower ratios suggest the market is discounting its operational risks but also recognising potential value for investors willing to accept the associated uncertainties.

However, the company’s financial performance and profitability metrics lag behind many competitors, which continue to demonstrate stronger growth and returns on equity. This divergence between valuation and quality metrics underpins the cautious upgrade to a Sell rating rather than a more positive Buy or Strong Buy recommendation.

Outlook and Investor Considerations

Investors considering Tejnaksh Healthcare should weigh the improved valuation against the company’s ongoing operational challenges and weak financial trends. The upgrade to Sell from Strong Sell reflects a more balanced view, acknowledging that the stock is no longer excessively overvalued but still carries significant risks due to flat earnings and low profitability.

Long-term investors may find the current price levels attractive if they believe the company can stabilise its earnings and improve return metrics. However, the negative five-year and three-year returns caution that recovery may be protracted and uncertain.

Given the micro-cap status and promoter-controlled shareholding, liquidity and governance factors should also be considered as part of a comprehensive investment analysis.

Summary of Rating Change

On 1 June 2026, MarketsMOJO revised Tejnaksh Healthcare Ltd’s Mojo Grade from Strong Sell to Sell, with a current Mojo Score of 31.0. The primary driver was the valuation grade upgrade from attractive to very attractive, supported by a PE ratio of 25.38, EV/EBITDA of 10.86, and a P/B ratio of 1.17. Despite this, quality grades remain weak due to negative profit growth and low ROE, while financial trends are flat and technical momentum is mixed.

This nuanced rating reflects a cautious stance, recognising valuation appeal but tempered by fundamental and operational headwinds.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today